What does “biosynthetic heparin” mean, and how is Google Patents related?
Heparin is a highly sulfated sugar used as an anticoagulant. “Biosynthetic heparin” generally refers to heparin made through engineered biological pathways (rather than extracted from animal tissue). If you search Google Patents for that phrase, you’re typically looking for patent families that describe:
- engineered enzymes/cell systems that build heparin-like polysaccharides, or
- methods to produce heparin (or heparin fractions) with controlled structure/sulfation and then formulate it for therapeutic use.
Google Patents is a search platform, so it doesn’t itself confirm whether a specific application is granted; it just helps you find patent documents (applications, publications, continuations, etc.) that mention the technology.
How to search Google Patents for “biosynthetic heparin” and US applications
To find the US-specific filings connected to biosynthetic heparin, use a targeted Google Patents query and then filter to the US:
- Search terms to try in Google Patents:
- "biosynthetic heparin" AND (US OR "US")
- "synthetic heparin" (sometimes used in place of biosynthetic in older filings)
- heparin AND (engineered OR biosynthetic OR biosynthesis OR enzymatic)
- heparin AND (glycosaminoglycan OR polysaccharide) AND (production OR producing)
- Then narrow to:
- Jurisdiction: United States
- Document type: application (or “patent” if you want granted ones too)
- Assignee: if you already know the company/academic group name
If you paste the exact Google Patents link or the publication number you’re seeing (for example, an “US20xx…” number), I can help interpret whether it’s an application vs. a granted patent, what the claims appear to cover, and what the main technical approach is.
What to look for in an “US application” page (so you can tell what it really covers)
When you open a US filing on Google Patents, the most useful fields for understanding “biosynthetic heparin” are usually:
- The assignee/applicant (who is trying to own the technology)
- The title and abstract (whether it describes the production pathway, purification, or medical use)
- Claim 1 (often shows whether they claim the method of making, the engineered system, the product structure, or a medical/composition use)
- Publication number and date (US application publications are often labeled like US20xx…)
- Prior art/back references (helpful for mapping what’s novel)
Are there typically US patents on heparin production that aren’t “biosynthetic”?
Yes. Many heparin-related US patent filings focus on:
- extraction and purification improvements for animal-derived heparin,
- chemical or chemo-enzymatic modifications,
- heparin formulations/dosing systems,
- analytical methods to characterize heparin structure.
So “biosynthetic heparin” results are most reliable when the document explicitly discusses engineered biosynthesis, fermentation, or biosynthetic pathway construction rather than extraction or reprocessing.
Can companies get exclusivity even if the exact “biosynthetic heparin” wording isn’t used?
They can. Patent searches sometimes miss relevant filings because applicants use different phrasing (for example, “chemoenzymatic synthesis,” “enzymatic production,” “glycosyltransferase-based synthesis,” or similar). If you only search for the exact phrase “biosynthetic heparin,” you may miss closely related claims.
Want me to pinpoint a specific US application?
Share one of the following and I’ll map it directly:
- the Google Patents URL, or
- the publication/patent number (e.g., US20xx… or USxxxxxxx), or
- the company/assignee name you think is behind it.
With that, I can tell you what the US application claims and whether it appears to cover the biosynthetic process, the resulting product (heparin/fragment), and/or therapeutic use.
Sources
No specific patent document or DrugPatentWatch.com entry was provided in your message, so I did not cite external sources.